Related Experiment Video
Updated: Aug 5, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Pharmacogenetics in cardiovascular antithrombotic therapy
Francisco Marín1, Vanessa Roldán, Rocío González-Conejero
1Cardiology Department, Hospital General Universitario, C/ Pintor Baeza s/n, Alicante, Spain. fcomarino@hotmail.com
Current Medicinal Chemistry. Cardiovascular and Hematological Agents
|October 28, 2005
Summary
Genetic variations influence how individuals respond to antithrombotic drugs, impacting treatment efficacy for thrombosis and cardiovascular diseases. Understanding these pharmacogenetic factors is key to improving patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Pharmacogenetics
- Genetics
Background:
- Thrombosis is a primary cause of coronary heart disease and stroke, necessitating antithrombotic therapy.
- Current antithrombotic treatments show limited clinical benefits due to significant inter-individual heterogeneity in patient response.
- Identifying factors contributing to this heterogeneity is crucial for optimizing therapeutic strategies.
Purpose of the Study:
- To explore the influence of genetic factors on the efficacy of antithrombotic drugs.
- To analyze how specific genetic polymorphisms modulate individual responses to commonly used antithrombotic medications.
Main Methods:
- Review of existing literature on pharmacogenetics and antithrombotic therapy.
- Analysis of genetic polymorphisms affecting drug disposition, metabolism, transporters, and targets.
- Examination of the impact of these polymorphisms on drug efficacy and side effects.
Main Results:
- Genetic polymorphisms significantly contribute to inter-individual variability in response to antithrombotic agents.
- Specific gene variants can alter drug metabolism, target interaction, and overall treatment effectiveness.
- Understanding these genetic influences can help predict patient response and tailor antithrombotic therapy.
Conclusions:
- Pharmacogenetics offers a promising avenue for personalizing antithrombotic treatment strategies.
- Identifying genetic markers can help mitigate treatment failures and adverse events associated with antithrombotic drugs.
- Further research into genetic influences is essential for improving the clinical application of antithrombotic therapies.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...